EnsiliTech

EnsiliTech is pioneering a novel, patent-protected stabilization platform called ensilication, which protects biomolecules from thermal degradation without requiring a cold chain. The technology addresses a critical global challenge: the estimated 25% vaccine wastage and $35B annual cost due to cold chain failures. As a private, pre-revenue company, EnsiliTech is in the pre-clinical development stage, building partnerships to apply its platform across vaccines, antibodies, and other biologics to improve shelf-life, reduce costs, and lower the carbon footprint of global health programs.

Ensilication: a patent-protected method for encasing thermally unstable biomolecules within a silica network to prevent degradation at temperatures from -80 to +50°C, eliminating the need for cold-chain storage and transport.

EnsiliTech competes with other biostabilization technologies, including advanced lyophilization (freeze-drying), spray-drying, and alternative encapsulation methods using sugars or other polymers. Its differentiation lies in the gentle, silica-based process that avoids harsh drying conditions and claims broad applicability across biomolecule types.